

For More Information:

Layna L. Mendlinger

info@vtivision.com**[For immediate release](#)****Visioneering Technologies Announces Publication of Peer-Reviewed Data from a 6-Year Myopia Progression Study in *Clinical Ophthalmology*****Highlights**

- Retrospective cohort analysis - 196 real-world subjects, 6 years of data recently published in the peer-reviewed journal [Clinical Ophthalmology](#)
- The article entitled, **Reduction of Myopic Progression Using a Multifocal Soft Contact Lens: A Retrospective Cohort Study**, serves to share the latest research across both specialties of Optometry and Ophthalmology, validated through the peer-review process
- Authors include some of the industry's myopia experts: Jeffrey Cooper MS, OD, FAAO, Brett O'Connor, OD, Thomas Aller, OD, FBCLA, Sally M. Dillehay, OD, EdD, Katherine Weibel, OD, Douglas P. Benoit, OD, FAAO
- Results:
 - 95% of subjects showed a decrease in myopia progression, with 78% showing a decrease of 70% or more, as compared to baseline
 - The average rate of myopia progression slowed by 85% as compared to baseline from 6-72 months
 - Axial lengthening was slowed to the normal rate of change expected for non-myopic children of a similar age range

Atlanta, Georgia, Friday, July 8, 2022: US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses ('NaturalVue MF') **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering', 'VTI' or 'the Company') today announced that peer-reviewed data from their extensive, retrospective cohort analysis spanning over six years, were published in the journal *Clinical Ophthalmology*. The study reported data with 196 real-world subjects on the impact of its NaturalVue MF on children with myopia, or near-sightedness. VTI's NaturalVue MF contact lenses feature the innovative Neurofocus Optics® Technology, which uses an extended-depth-of-focus design to address known optical risk factors associated with the progression of myopia.

Clinical Ophthalmology is an international, peer-reviewed, journal covering all subspecialties within ophthalmology. The publication of the peer-reviewed data in this journal provides further validation of NaturalVue MF's effectiveness in slowing or stopping myopia progression in real-world practice.

Chief Medical Officer, Dr. Kuang-mon (Ashley) Tuan, OD, PhD, FAAO, commented "The data being published in *Clinical Ophthalmology* serves to unite Optometry and Ophthalmology to educate and inform to the latest research in the fight against myopia progression. We hope that eye care practitioners worldwide will appreciate the importance of our receiving validation from a highly respected and peer-reviewed journal for our real-world study."

The data showed that 95% of subjects wearing NaturalVue MF experienced a decrease in myopia progression as compared to baseline. Additionally, 78% of wearers showed a decrease in myopia progression of 70% or greater. The average myopia progression slowed by approximately 0.85D or 85% compared to baseline, which was statistically significant at all points in time (P<0.05.) The average myopia progression while wearing NaturalVue MF never exceeded more than about 0.25D from baseline. Axial length change was measured for a subset of the



study subjects** Significantly, the average axial elongation change was approximately 0.10 mm per year through 47 months of follow-up, which approximates that expected for a non-myopic child of a similar age range and shows that NaturalVue MF contact lenses help to reduce the anatomical cause of myopia progression.

The publication reported on the effectiveness of NaturalVue MF compared to changes observed in children not wearing the lenses, an age and ethnicity matched virtual control group (N=188) developed from 63 randomized clinical trials was used. This analysis demonstrated a Cumulative Absolute Reduction of axial Elongation (Termed a 'CARE' value) of 0.45 mm less axial elongation over 3 years for NaturalVue MF than would be expected for age and ethnicity matched children.

To provide the eye care community and potential corporate partners with additional data, VTI has initiated PROTECT Clinical Study (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial), an international randomized controlled clinical trial (RCT) to test its NaturalVue® Multifocal Contact Lenses in myopia progression control. The landmark study has enrolled patients in sites in Canada, the United States and Hong Kong, and is in the process of adding sites in Singapore and Australia. The Company expects to have interim 1-year data from the PROTECT Clinical Study in the second half of 2023.

About Visioneering Technologies, Inc.

Visioneering Technologies Inc. (ASX: VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day™ Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, visit www.vtivision.com or call 844-884-5367, ext. 104.

MKT-VTI-PR83

**Statistically significant.